Message Number: SG10871 | New FHL Archives Search
From: Pam Sessoms
Date: 2004-09-29 15:54:20 UTC
Subject: Re: Requesting Information re: Lupron
To: ferrethealth@smartgroups.com
cc: lvfzbtts@tampabay.rr.com
Message-ID: <Pine.A41.4.44+UNC.0409291150140.52968-100000@login7.isis.unc.edu>

> My mission is to provide him with documentation about Lupron therapy
> PUBLISHED by other veterinarians in REPUTABLE veterinary magazines or
> books.

Dee, I don't have my books at hand, but here are two published sources
that he might like to read. One is from ExoticDVM magazine and is
available as a sample article on the web. The other is in JAVMA, so he
likely already has that or if not will be able to get it easily enough.
Citations are below.

Best wishes,

-Pam S.

ExoticDVM. 1999 1(4):19-22. Ferret Adrenal Disease: Alternatives to
Surgery. by Cathy Johnson-Delaney.
full text freely available at:
http://www.exoticdvm.com/pdfs/sample1-4.pdf

============================

J Am Vet Med Assoc. 2001 Apr 15;218(8):1272-4.

Leuprolide acetate treatment of adrenocortical disease in ferrets.

Wagner RA, Bailey EM, Schneider JF, Oliver JW.

Department of Laboratory Animal Resources, School of Health Sciences,
University of Pittsburgh, PA 15261, USA.

OBJECTIVE: To determine the effects of leuprolide acetate, a long-acting
gonadotropin-releasing hormone analog, in ferrets with adrenocortical
diseases. DESIGN: Case series. ANIMALS: 20 ferrets with adrenocortical
disease diagnosed on the basis of clinical signs and plasma sex hormone
concentrations. PROCEDURE: Ferrets were treated with leuprolide (100
microg, IM, once), and plasma hormone concentrations were measured before
and 3 to 6 weeks after treatment. RESULTS: Leuprolide treatment resulted
in significant reductions in plasma estradiol, 17
alpha-hydroxyprogesterone, androstenedione, and dehydroepiandrosterone
concentrations and eliminated or reduced clinical signs associated with
adrenocortical disease. Decreases in vulvar swelling, pruritus, and
undesirable sexual behaviors and aggression were evident 14 days after
treatment; hair regrowth was evident by 4 weeks after treatment. The
response to treatment was transitory, and clinical signs recurred in all
ferrets. Mean +/- SEM time to recurrence was 3.7 +/- 0.4 months (range,
1.5 to 8 months). CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that
leuprolide can be safely used to temporarily eliminate clinical signs and
reduce sex hormone concentrations in ferrets with adrenocortical diseases.
However, the safety of long-term leuprolide use in ferrets has not been
investigated, and the long-term effects of leuprolide in ferrets with
nodular adrenal gland hyperplasia or adrenal gland tumors are unknown.

PMID: 11330611 [PubMed - indexed for MEDLINE]